Volume 1, # 6 - October, 1995
Table of Contents
|
| STATE-OF-THE-ART MANAGEMENT OF CANCER |
| MALIGNANT MELANOMA - PART II |
| New Drugs and Modalities in Development for the Treatment of Malignant Melanoma |
142 |
| Immunotherapy Approaches for the Treatment of Malignant Melanoma |
142 |
| Systematically-delivered Cytokines as Immunomodulators |
143 |
| Systematically-delivered Interferons |
143 |
| Inteferon-alpha |
143 |
| IFN-alpha 2b combined with Melacine |
143 |
| IFN-alpha 2a/retinoid combinations |
144 |
| IFN-gamma |
144 |
| Systematically-delivered Interleukins |
144 |
| Interleukin-2 |
144 |
| IL-2 analogs |
144 |
| Cell Therapeutics |
144 |
| IL-2/IFN-alpha combinations |
145 |
| Il-2/IL-1 beta combinations |
145 |
| IL-2.loxoribine combinations |
145 |
| IL-4 |
145 |
| IL-12 |
145 |
| Active Specific Immunotherapy-Tumor Cell Vaccines |
145 |
| Ribi ImmunoChem Research |
147 |
| Lidak Pharmaceuticals |
147 |
| Cytel |
147 |
| StressGen Biotechnologies |
147 |
| Active Specific Immunotherapy-Gene Transfer |
148 |
| Immunex |
149 |
| Somatix Therapy |
149 |
| Targeted Genetics |
149 |
| Boehringer Ingelheim |
149 |
| RGene Therapeutics |
149 |
| Genetic Therapy |
149 |
| Vical |
150 |
| Therion Biologics |
150 |
| Active Specific Immunotherapy-Monoclonal Antibodies |
150 |
| ImClone Systems |
150 |
| Adoptive Immunotherapy |
150 |
| Cellcor |
151 |
| Passive Immunotherapy |
151 |
| Gene Transfer-HSV Thymidine Kinase Gene |
150 |
| Pasteur Institute |
152 |
| Genopoietic |
152 |
| Other Agents in Development |
152 |
| Dovetail Technologies |
152 |
| Melatonin |
152 |
| Melanoma Inhibitory Activity (MIA) Protein |
152 |
| SunPharm |
152 |
| Cancer Research Campaign Technology |
152 |
| Isolated Limb Perfusion |
158 |
| MEETING COVERAGE |
OPPORTUNISTIC INFECTIONS IN CANCER PATIENTS
A Report From the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
San Francisco, CA - September 17-20, 1995 |
| Bacterial Infections |
159 |
| Enterococcus faecium (VREF) |
159 |
| Viridians Streptococcal Bacteremia |
160 |
| New Therapeutic Modalities for Opportunistic Bacterial Infections |
160 |
| Meropenem |
160 |
| Combination of Ciprofloxacin and Piperacillin |
160 |
| Viral Infections |
160 |
| Cytomegalovirus (CMV) |
160 |
| New Therapeutic Modalities for Opportunistic Viral Infections |
161 |
| Low-dose intravenous acyclovir |
161 |
| Varicella zoster immune globulin prophylaxis |
161 |
| Fungal Infections |
161 |
| Pneumocystis carinii Pneumonia |
162 |
| New Therpeutic Modalities for Opportunistic Fungal Infections |
163 |
| Itraconazole in invasive pulmonary aspergillosis |
163 |
| Amphotericin B lipid complex |
163 |
| Liposomal nystatin |
163 |
| Bloodstream Infections |
164 |
| TECHNOLOGY UPDATE |
NUCLEAR MEDICINE
|
| Unique Applications of Nuclear Medicine Are Expanding in Oncology |
164 |
| Pet/Spect and High Energy Imaging |
164 |
| FDG Imaging Based on Cellular Metabolism |
164 |
| Evaluation of solitary pulmonary nodules in lung cancer |
165 |
| Whole-body nuclear imaging |
165 |
| Determination of lung cancer that has spread to the mediastinum |
165 |
| Differentiation between malignant and benign breast tumors |
165 |
| Scinti-Mammography and Evaluation of Tumors in the Dense Breast |
165 |
| Detection of Tumors Exhibiting Multidrug Resistance |
166 |
| Radiolabeled Somatostatin for Selectively Targeting Disease |
166 |
| Indium-labeled Somatostatin |
167 |
| Mallinckrodt Medical |
167 |
| CIS-US |
167 |
| Technetium-labeled Peptides |
167 |
| Diatech |
167 |
| Radiotracers that Bind to Other Somatostatin Receptor Subtypes |
167 |
